{"analyses":[{"ciLowerLimit":"0.710","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.085","estimateComment":"The Hazard Ratio is based on a stratified Cox regression model including treatment as covariate, and histology, geographic region, and number of prior regimens for advanced STS as strata.","groupDescription":"The PFS and PFS rate at 3, 6, and 12 months (95% confidence interval (CI)) was calculated using Kaplan-Meier (K-M) product-limit method and Greenwood Formula. PFS was compared between the treatment arms using two-sided stratified log-rank test, stratified by histology, geographic region, and number of prior regimens for advanced STS.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"=0.2287","pValueComment":"P-value was calculated by 2-sided log-rank test, as stratified by histology, geographic region, and number of prior regimens for advanced STS.","paramType":"Hazard Ratio (HR)","paramValue":"0.877","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"2.8","value":"2.6"},{"groupId":"OG001","lowerLimit":"1.8","upperLimit":"2.7","value":"2.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"224"}],"units":"Participants"}],"description":"PFS was defined as the time from the date of randomization to the date of first documentation of disease progression, or date of death (whichever occurred first). The date of disease progression was defined as the date of radiologic disease progression as assessed by the investigator or designee based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Participants who did not have an event (i.e., participants who were lost to follow-up or who did not progress or die at the date of data cut-off), were censored. Participants who discontinued study treatment without disease progression were censored on the date of their last radiological assessment (scan date).","dispersionType":"95% Confidence Interval","groups":[{"description":"Eribulin mesylate at a dose of 1.4 mg/m\\^2 was administered IV as a bolus infusion over 2-5 minutes on Days 1 and 8 of every 21-day treatment cycle.","id":"OG000","title":"Arm A: Eribulin Mesylate"},{"description":"Dacarbazine at a dose of 850 mg/m\\^2, 1000 mg/m\\^2, or 1200 mg/m\\^2 (as selected by the PI or designee prior to randomization according to the participant's clinical status) was administered as an IV infusion over 15-30 minutes (or up to 60 minutes as per institutional guidelines) on Day 1 of every 21-day treatment cycle.","id":"OG001","title":"Arm B: Dacarbazine"}],"paramType":"MEDIAN","populationDescription":"FAS (ITT analysis set) included all participants who were randomized.","reportingStatus":"POSTED","timeFrame":"Randomization (day 1) to the date of first documentation of disease progression, or date of death (whichever occurred first), up to 5 years 5 months","title":"Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}